One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in Male adult patients with Fabry disease

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Najafian, Behzad ^a   Tøndel, Camilla ^b,c   Svarstad, Einar ^b,c   Sokolovkiy, Alexey ^a   Smith, Kelly ^a   Mauer, Michael ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE TRIHEXOSIDE; GLOBOTRIAOSYLCERAMIDE;

ADOLESCENT; ADULT; CELL SIZE; CLINICAL TRIAL; DRUG EFFECTS; ENZYME REPLACEMENT; EXOCYTOSIS; FABRY DISEASE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PODOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; CELL SIZE; ENZYME REPLACEMENT THERAPY; EXOCYTOSIS; FABRY DISEASE; HUMANS; MALE; MIDDLE AGED; PODOCYTES; TRIHEXOSYLCERAMIDES; YOUNG ADULT;

EID: 85020319240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152812     Document Type: Article

References (50)

1. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, et al. (1973) Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81: 157–171. PMID: 4683418
2. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750–760. PMID: 11694547
3. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933–1946. PMID: 12427118
4. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547–1557. PMID: 17409312
5. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146: 77–86. PMID: 17179052
6. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, et al. (2012) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27: 1042–1049. doi: 10.1093/ndt/gfr420 PMID: 21804088
7. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. N Engl J Med 345: 9–16. PMID: 11439963
8. Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, et al. (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24: 137–148. doi: 10.1681/ASN.2012030316 PMID: 23274955
9. Brinkkoetter PT, Ising C, Benzing T (2013) The role of the podocyte in albumin filtration. Nat Rev Nephrol 9: 328–336. doi: 10.1038/nrneph.2013.78 PMID: 23609563
10. Wiggins RC (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71: 1205–1214. PMID: 17410103
11. Najafian B, Svarstad E, Bostad L, Gubler MC, Tondel C, et al. (2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 79: 663–670. doi: 10.1038/ki.2010.484 PMID: 21160462
12. Patel V, O'Mahony C, Hughes D, Rahman MS, Coats C, et al. (2015) Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease. Heart 101: 961–966. doi: 10.1136/ heartjnl-2014-306782 PMID: 25655062
13. Sever S, Altintas MM, Nankoe SR, Moller CC, Ko D, et al. (2007) Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 117: 2095–2104. PMID: 17671649
14. Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, et al. (2010) Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 25: 2168–2177. doi: 10.1093/ndt/gfp528 PMID: 19833663
15. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, et al. (1978) Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13: 223–235. PMID: 418264
16. Tondel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51: 767–776. doi: 10.1053/j.ajkd.2007.12. 032 PMID: 18436087
17. Braendgaard H, Gundersen HJ (1986) The impact of recent stereological advances on quantitative studies of the nervous system. J Neurosci Methods 18: 39–78. PMID: 3540470
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612. PMID: 19414839
19. Gundersen HJ, Jensen EB (1985) Stereological estimation of the volume-weighted mean volume of arbitrary particles observed on random sections. J Microsc 138: 127–142. PMID: 4020857
20. Weibel E (1979) Elementary Introduction to Stereological Principles. In: Stereological Methods. In: ER W, editor. Practical Methods for Biological Morphometry. London, New York, Toronto, Sydney, San Francisco: Academic Press. pp. 9–62.
21. Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, et al. (2005) Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 16: 2953–2966. PMID: 16120818
22. Lee SH, Moon SJ, Paeng J, Kang HY, Nam BY, et al. (2015) Podocyte hypertrophy precedes apoptosis under experimental diabetic conditions. Apoptosis 20: 1056–1071. doi: 10.1007/s10495-015-1134-0 PMID: 25953318
23. Hodgin JB, Bitzer M, Wickman L, Afshinnia F, Wang SQ, et al. (2015) Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective. J Am Soc Nephrol.
24. LeSage GD, Robertson WE, Baumgart MA (1993) Bile acid-dependent vesicular transport of lysosomal enzymes into bile in the rat. Gastroenterology 105: 889–900. PMID: 8359656
25. Silverstein RL, Febbraio M (1992) Identification of lysosome-associated membrane protein-2 as an activation-dependent platelet surface glycoprotein. Blood 80: 1470–1475. PMID: 1520873
26. Tapper H, Sundler R (1990) Role of lysosomal and cytosolic pH in the regulation of macrophage lysosomal enzyme secretion. Biochem J 272: 407–414. PMID: 2268269
27. Chavez RA, Miller SG, Moore HP (1996) A biosynthetic regulated secretory pathway in constitutive secretory cells. J Cell Biol 133: 1177–1191. PMID: 8682857
28. Coorssen JR, Schmitt H, Almers W (1996) Ca2+ triggers massive exocytosis in Chinese hamster ovary cells. EMBO J 15: 3787–3791. PMID: 8670883
29. Reddy A, Caler EV, Andrews NW (2001) Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 106: 157–169. PMID: 11511344
30. Rehder V, Jensen JR, Kater SB (1992) The initial stages of neural regeneration are dependent upon intracellular calcium levels. Neuroscience 51: 565–574. PMID: 1488115
31. Arantes RM, Andrews NW (2006) A role for synaptotagmin VII-regulated exocytosis of lysosomes in neurite outgrowth from primary sympathetic neurons. J Neurosci 26: 4630–4637. PMID: 16641243
32. Pena K, Coblenz J, Kiselyov K (2015) Brief exposure to copper activates lysosomal exocytosis. Cell Calcium 57: 257–262. doi: 10.1016/j.ceca.2015.01.005 PMID: 25620123
33. Kukic I, Kelleher SL, Kiselyov K (2014) Zn2+ efflux through lysosomal exocytosis prevents Zn2 +-induced toxicity. J Cell Sci 127: 3094–3103. doi: 10.1242/jcs.145318 PMID: 24829149
34. Gerasimenko JV, Gerasimenko OV, Petersen OH (2001) Membrane repair: Ca(2+)-elicited lysosomal exocytosis. Curr Biol 11: R971–974. PMID: 11728325
35. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, et al. (2006) Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J Biol Chem 281: 20483–20493. PMID: 16714284
36. Fukuda T, Ewan L, Bauer M, Mattaliano RJ, Zaal K, et al. (2006) Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 59: 700–708. PMID: 16532490
37. Liao G, Yao Y, Liu J, Yu Z, Cheung S, et al. (2007) Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brain. Am J Pathol 171: 962–975. PMID: 17631520
38. Settembre C, Fraldi A, Jahreiss L, Spampanato C, Venturi C, et al. (2008) A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17: 119–129. PMID: 17913701
39. Fraldi A, Annunziata F, Lombardi A, Kaiser HJ, Medina DL, et al. (2010) Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO J 29: 3607–3620. doi: 10.1038/emboj.2010.237 PMID: 20871593
40. Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, et al. (2011) Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell 21: 421–430. doi: 10.1016/j.devcel.2011. 07.016 PMID: 21889421
41. Kinugasa S, Tojo A, Sakai T, Fujita T (2010) Silver-enhanced immunogold scanning electron microscopy using vibratome sections of rat kidneys: detection of albumin filtration and reabsorption. Med Mol Morphol 43: 218–225. doi: 10.1007/s00795-010-0500-9 PMID: 21267698
42. Ogasawara R, Yoshida Y, Tohyama K, Satoh Y, Suwabe A (2009) Isolated rat alveolar type II cells protrude intracellular lamellar bodies by forming bubble-like structures during surfactant secretion. Cell Tissue Res 335: 397–405. doi: 10.1007/s00441-008-0717-2 PMID: 19023598
43. Miklavc P, Wittekindt OH, Felder E, Dietl P (2009) Ca2+-dependent actin coating of lamellar bodies after exocytotic fusion: a prerequisite for content release or kiss-and-run. Ann N Y Acad Sci 1152: 43–52. doi: 10.1111/j.1749-6632.2008.03989.x PMID: 19161375
44. van den Berg JG, van den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S (2004) Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 66: 1901–1906. PMID: 15496161
45. Deegens JK, Dijkman HB, Borm GF, Steenbergen EJ, van den Berg JG, et al. (2008) Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 74: 1568–1576. doi: 10.1038/ki.2008.413 PMID: 18813290
46. Ellis EN, Steffes MW, Chavers B, Mauer SM (1987) Observations of glomerular epithelial cell structure in patients with type I diabetes mellitus. Kidney Int 32: 736–741. PMID: 3430959
47. Najafian B, Mauer M, Hopkin RJ, Svarstad E (2013) Renal complications of Fabry disease in children. Pediatr Nephrol 28: 679–687. doi: 10.1007/s00467-012-2222-9 PMID: 22898981
48. Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, et al. (2010) A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol 19: 293–301. doi: 10.1016/j.carpath.2009.05.003 PMID: 19631563
49. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, et al. (2006) Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 448: 337–343. PMID: 16315019
50. Mauer M, Glynn E, Svarstad E, Tondel C, Gubler MC, et al. (2014) Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS One 9: e112188. doi: 10.1371/ journal.pone.0112188 PMID: 25386848